← Leaderboards
Joseph Austin Delaney
University Of Washington
$3,470,248
Attributed
$10,143,331
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,143,331 · 5
By mechanism
R01$5,121,113 · 1
U24$2,706,512 · 1
U01$1,527,788 · 1
R21$787,918 · 2
Top collaborators
- Heidi M. Crane15 shared
- Kristina Anne Crothers4 shared
- Geetanjali Chander3 shared
- Lydia Nicole Drumright3 shared
- Susan Heckbert3 shared
- Andrew William Hahn2 shared
- Robert C Kaplan2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Heidi M. Crane$25,961,202
- Sabrina Oesterle$5,856,966
- Susan Heckbert$14,216,326
- Stephen R Dager$7,709,318
- Kimberly F Balsam$1,992,808
Others in their field
Top investigators on “Antiretroviral Therapy”
- James Dennis Neaton · Northwestern University$279,044,427
- Lawrence Corey · Fred Hutchinson Cancer Center$278,220,635
- Constance Ann Benson · University Of California, San Diego$241,336,455
- Carol Nesel · Westat$188,148,170
- Judith S. Currier · University Of California Los Angeles$182,467,520
- Barbara Driver · Westat, Inc.$170,789,549
Research focus
Antiretroviral TherapyCohortRisk FactorsSitePersonsCaringCohort StudiesResourcesAgingPatient Outcomes AssessmentsMultidisciplinaryPharmaceutical PreparationsClinical CareClinical DataComplexCardiovascular DiseasesPrevalenceBloodCoagulation ProcessLinkInterestDiabetes MellitusSample SizeRacial Diversity
Grant awards (17)
HIV and Substance Use Cohort Coordinating Center for Emerging and High Impact Scientific Cross Cohort Studies: HIV SUCCESS$929,341
U24 · FY2025 · DA
Links between Cardiovascular disease, Lung disease, and Obstructive sleep apnea in HIV: Understanding complex patients$667,628
R01 · FY2025 · HL
HIV and Substance Use Cohort Coordinating Center for Emerging and High Impact Scientific Cross Cohort Studies: HIV SUCCESS$838,133
U24 · FY2024 · DA
Links between Cardiovascular disease, Lung disease, and Obstructive sleep apnea in HIV: Understanding complex patients$675,830
R01 · FY2024 · HL
HIV and Substance Use Cohort Coordinating Center for Emerging and High Impact Scientific Cross Cohort Studies: HIV SUCCESS$939,038
U24 · FY2023 · DA
Links between Cardiovascular disease, Lung disease, and Obstructive sleep apnea in HIV: Understanding complex patients$685,518
R01 · FY2023 · HL
Links between Cardiovascular disease, Lung disease, and Obstructive sleep apnea in HIV: Understanding complex patients$739,732
R01 · FY2022 · HL
Marijuana policy change impact on patterns of marijuana and other harmful substance use among people living with HIV: A mixed methods evaluation$194,375
R21 · FY2020 · DA
Marijuana policy change impact on patterns of marijuana and other harmful substance use among people living with HIV: A mixed methods evaluation$233,250
R21 · FY2019 · DA
Seek, Test, Treat, and Retain Data Harmonization Coordinating Center$153,227
U01 · FY2019 · DA · contact PI
Seek, Test, Treat, and Retain Data Harmonization Coordinating Center$684,004
U01 · FY2018 · DA · contact PI
Cardiovascular, Pulmonary & Hematological Disease in HIV: Prevention & Treatment$777,434
R01 · FY2017 · HL
Seek, Test, Treat, and Retain Data Harmonization Coordinating Center$690,557
U01 · FY2017 · DA · contact PI
Cardiovascular, Pulmonary & Hematological Disease in HIV: Prevention & Treatment$763,655
R01 · FY2016 · HL
Cardiovascular, Pulmonary & Hematological Disease in HIV: Prevention & Treatment$811,316
R01 · FY2015 · HL
CVD and inflammation across the lifespan in HIV infected adults and children$157,526
R21 · FY2014 · HL · contact PI
CVD and inflammation across the lifespan in HIV infected adults and children$202,767
R21 · FY2013 · HL · contact PI